medigraphic.com

2012, Number 2

<< Back Next >>

Rev Fac Med UNAM 2012; 55 (2)

Parvovirus B19: Laboratory diagnosis Abstract

García GR,Basilio HD,Hernández RA

Language: Spanish
References: 40
Page: 4-10
PDF size: 143.65 Kb.


ABSTRACT

Parvovirus B19 (B19) is the only known human pathogenic parvovirus. The spectrum of illness to which B19 is associated includes a wide range of diseases: erythema infectiosum, thrombocytopenia or granulocytopenia, aplastic crisis or hemolytic anemia in immunocompromised patients. The laboratory diagnosis of Parvovirus B19 infection is primarily confirmed by the detection of IgM antiviral antibodies using the ELISA technique, which is directed against both conformational and linear epitopes of VP1 and VP2 capsid. When IgM response declines, an IgG immune-response against structural proteins VP1 and VP2 becomes prominent and can detected by immunofluorescence, ELISA and Western blot. Polymerase chain reaction is now used as a routine analysis as well as complement or alternative to serology.


REFERENCES

  1. Cossat YE, Field AM, Cant B, Widdows D. Parvoviruslike particles in human sera. Lancet. 1975;1:72-3.

  2. Brown KE. Heamatological consequences of parvovirus B19 infection. Bailliere´s Clinical Hematology. 2000;13: 245-59.

  3. Kishore J, Kapoor A. Erythrovirus B19 infection in human. Indian J Med Res. 2000;112:149-64.

  4. Portillo-Carrillo M, Velásquez-Jones L, Gómez-Chico VR y col. Aplasia adquirida de la serie roja por infección por parvovirus B19 en una adolescente con transplante renal. Bol Med Hosp. Infant Mex. 2006;63:255-63.

  5. Enders M, Schalasta G, Baisch C y col. Human parvovirus B19 infection during pregnancy – Value of modern molecular and serological diagnostics. J Clin Virol. 2006;35: 400-6.

  6. Pankuweit S, Moll R, Baandrup U, Portig I, Hufnagel G, Maisch B. Prevalence of the Parvovirus B19 genome in endomyocardial biopsy specimens. Hum pathol. 2003;3497- 503.

  7. Fixer J and Styles L. Sickle cell disease. In Vichinsky E, Walter MC and Feusner J, editores. Pediatric Clin N AM. 2000;149:1193-210.

  8. Mustafa MM, McClain KL. Diverse hematologic effects of Parvovirus B19 infection. In (ed). Pediatric Clin NAM. 1996;43:809-21.

  9. Heegaard ED, Brown KE. Human Parvovirus B19. Clin Microbiol Ver. 2002;15:485-505.

  10. Söderiund M, Brown CS, Spaan WJM, Hedman L and Hedman K. Epitopes Type Specific Ig Responses to Capsid Proetins VP1 and VP2 of Human Parvovirus B19. J Infect Dis. 1995;172:1431-6.

  11. Servant A, Laperche S, Lallemand F. Genetic diversity within human erythrovirus of three genotypes. J Virol 2002;76:9124- 34.

  12. Cohen BJ, Gandhi J and Clewley JP. Genetic variants of parvovirus B19 identified in the United Kingdon: Implications for diagnostic testing. J Clin Virol. 2006;36: 152-5.

  13. Kurtzman G, Frickhofen N, Kimball J, Jenkins DW, Nienhuis AW, Young NS. Pure red-cell aplasia of 10 years´duration due to persistent Parvovirus B19 infection and it´s cure with immunoglobulin therapy.N Engl J Med. 1989;321:519-23.

  14. Artinos de OS, Bastos CLA, de Madeiros PAC, Faillace TF, Setúbal S, Pereira NJ. Clinical and epidemiological aspects of human Parvovirus B19 infection in an urban area in Brazil (Niterói city area state of Rio de Janeiro, Brazil). Mem Inst Oswaldo Cruz. 2002;97:965-70.

  15. Grangeot-Keros L. Molecular disgnosis of viral materno- -fetal infections. Ann Pharm Fr. 2003;61:259-64.

  16. Aslan B, Serin MS, Aslan, et al. 2007. Detection of parvovirus B19 in synovial fluids of patients with osteoarthritis. Diagnostic Microbiology and Infectious Disease. 2007;60: 381-5.

  17. Tercan US, Ozunel L, Kasifoglu N, Akgun Y. The investigation of Parvovirus B19 Infection in Patientes with Haematological Disorders by Using PCR and ELISA techniques. Brazilian J Infect Dis (BJID). 2007;11:327-30.

  18. Lundvist A, Tolfvenstam T, Brytting M, Stolt CM, Hedman K, Broliden K. Prevalence of Parvovirus B19 DNA in bone marrow of patients with haematological disorders. Scand J Infect Dis. 1999;31:119-22.

  19. Peterlana D, Puccetti A, Corrocher R, Lunardi C. Serologic and molecular detection of human Parvovirus B19 infection. Clinica Chimica Acta. 2006;372:14-23.

  20. Beersma MFC, Claas ECJ, Sopaheluakan T, Kroes ACM. Parvovirus B19 viral loads in relation to VP1 and VP2 antibody responses in diagnostic blood samples. J Clin Virol. 2005;34:71-5.

  21. Cossat YE, Field AM, Cant B, Widdows D. Parvoviruslike particles in human sera. Lancet. 1975;1:72-3.

  22. Brown KE. Heamatological consequences of parvovirus B19 infection. Bailliere´s Clinical Hematology. 2000;13: 245-59.

  23. Kishore J, Kapoor A. Erythrovirus B19 infection in human. Indian J Med Res. 2000;112:149-64.

  24. Portillo-Carrillo M, Velásquez-Jones L, Gómez-Chico VR y col. Aplasia adquirida de la serie roja por infección por parvovirus B19 en una adolescente con transplante renal. Bol Med Hosp. Infant Mex. 2006;63:255-63.

  25. Enders M, Schalasta G, Baisch C y col. Human parvovirus B19 infection during pregnancy – Value of modern molecular and serological diagnostics. J Clin Virol. 2006;35: 400-6.

  26. Pankuweit S, Moll R, Baandrup U, Portig I, Hufnagel G, Maisch B. Prevalence of the Parvovirus B19 genome in endomyocardial biopsy specimens. Hum pathol. 2003;3497- 503.

  27. Fixer J and Styles L. Sickle cell disease. In Vichinsky E, Walter MC and Feusner J, editores. Pediatric Clin N AM. 2000;149:1193-210.

  28. Mustafa MM, McClain KL. Diverse hematologic effects of Parvovirus B19 infection. In (ed). Pediatric Clin NAM. 1996;43:809-21.

  29. Heegaard ED, Brown KE. Human Parvovirus B19. Clin Microbiol Ver. 2002;15:485-505.

  30. Söderiund M, Brown CS, Spaan WJM, Hedman L and Hedman K. Epitopes Type Specific Ig Responses to Capsid Proetins VP1 and VP2 of Human Parvovirus B19. J Infect Dis. 1995;172:1431-6.

  31. Servant A, Laperche S, Lallemand F. Genetic diversity within human erythrovirus of three genotypes. J Virol 2002;76:9124- 34.

  32. Cohen BJ, Gandhi J and Clewley JP. Genetic variants of parvovirus B19 identified in the United Kingdon: Implications for diagnostic testing. J Clin Virol. 2006;36: 152-5.

  33. Kurtzman G, Frickhofen N, Kimball J, Jenkins DW, Nienhuis AW, Young NS. Pure red-cell aplasia of 10 years´duration due to persistent Parvovirus B19 infection and it´s cure with immunoglobulin therapy.N Engl J Med. 1989;321:519-23.

  34. Artinos de OS, Bastos CLA, de Madeiros PAC, Faillace TF, Setúbal S, Pereira NJ. Clinical and epidemiological aspects of human Parvovirus B19 infection in an urban area in Brazil (Niterói city area state of Rio de Janeiro, Brazil). Mem Inst Oswaldo Cruz. 2002;97:965-70.

  35. Grangeot-Keros L. Molecular disgnosis of viral materno- -fetal infections. Ann Pharm Fr. 2003;61:259-64.

  36. Aslan B, Serin MS, Aslan, et al. 2007. Detection of parvovirus B19 in synovial fluids of patients with osteoarthritis. Diagnostic Microbiology and Infectious Disease. 2007;60: 381-5.

  37. Tercan US, Ozunel L, Kasifoglu N, Akgun Y. The investigation of Parvovirus B19 Infection in Patientes with Haematological Disorders by Using PCR and ELISA techniques. Brazilian J Infect Dis (BJID). 2007;11:327-30.

  38. Lundvist A, Tolfvenstam T, Brytting M, Stolt CM, Hedman K, Broliden K. Prevalence of Parvovirus B19 DNA in bone marrow of patients with haematological disorders. Scand J Infect Dis. 1999;31:119-22.

  39. Peterlana D, Puccetti A, Corrocher R, Lunardi C. Serologic and molecular detection of human Parvovirus B19 infection. Clinica Chimica Acta. 2006;372:14-23.

  40. Beersma MFC, Claas ECJ, Sopaheluakan T, Kroes ACM. Parvovirus B19 viral loads in relation to VP1 and VP2 antibody responses in diagnostic blood samples. J Clin Virol. 2005;34:71-5.




2020     |     www.medigraphic.com